Top Glove's 3Q net loss narrows q-o-q on higher selling prices, cost optimisation
https://theedgemalaysia.com/node/671455
Replenishment activity picks up among customers, with the key US market continue to chart growth.
Company’s sales volume continues to rise month-on-month and the trend is expected to pick up in subsequent quarters, underpinned by inventory rebuilding by distributors.
Sales volume had strengthened 25% to 30% month-on-month, bringing utilisation rate to 65% to 70% versus our assumption of 55%.
Management is optimistic that average selling prices (ASPs) would rise by 5% to 15% or US$0.80 to US$1.50 per 1,000 pieces due to the uptick in demand and mitigation against the appreciating ringgit against the US dollar.
Exports to the United States, which account for 28% to 30% of the group’s geographical sales mix.
Weakening of predatory pricing by Chinese glovemakers as their capacity utilisation rises above 90% while revised US trade measures on gloves from China would see tariffs rising 50% in 2025 and 100% in 2026.
Head towards equilibrium in 2026 when there is no more net new capacity coming onstream while the global demand for gloves continues to rise by 15% per year.
Tariffs being imposed on Chinese gloves may lead to US distributors shifting their purchase to Malaysian glovemakers
From February 2025, Chinese medical gloves face 60% tariffs from 50% and 110% tariffs in 2026 from 100%.
Such tailwinds allowed Top Glove to raise the average selling price (ASP) for its US nitrile gloves export by about US$1 per thousand pieces since Nov 24 and eventually towards the pre-pandemic level of US$23 per thousand pieces in 2025,” it said. Top Glove’s nitrile glove ASP stands at US$20 currently.
Chinese glovemakers dump their excess supply in Europe, where Top Glove’s sales have declined 3% to 5% but this has been largely offset by a 5% month-on-month rise in January 2025 in US sales.
Moving forward, we foresee Top Glove’s US sales mix increasing to 25% to 30% of total sales in 2025 (first quarter ended Nov 30, 2024 (1Q25: 18%), with the Europe region’s sales mix easing off towards 35% to 40% (1Q25: 47%).
Users browsing this forum: No registered users and 1 guest